“…Sustained release intravitreal dexamethasone (DEX) implant, available as Ozurdex (Allergan, Inc, Irvine, CA), is approved for the treatment of diabetic macular edema (DME) following a randomized, masked, sham-controlled phase III clinical trial that demonstrated its efficacy and safety 1 . Endophthalmitis following intravitreal injections is not uncommon owing to the increasing number of injections; 2 however, there are very few reports of endophthalmitis after an intravitreal DEX implant 1, 3, 4, 5. This case adds to the literature on complications following administration of an intravitreal DEX implant and discusses the challenges faced while managing this scenario.…”